Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

nL-TARD-001

Phase 2Small molecule

Nn-Lorem Foundation

nL-TARD-001 is one of 14 small molecule programs targeting ALS. It is currently in Phase 2.

1

Indications

1

Total Trials

1

Active Trials

13

Competitors

Pipeline

Status by Indication[3][1]

Indication

ALSActive, not recruiting

ALSPhase 2

Active, not recruiting

Competition

Competitive Landscape

16 competitors in ALS

#DrugCompanyPhaseTrials

Spinraza

Evrysdi

Tirosint

IInstitut Jerome Lejeune

Revia

Ranexa

MMenarini International Operations Luxembourg SA

Iglarlixi

Salbutamol

Balstilimab

Buspirone Hydrochloride

Zalifrelimab

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

ALS1 trial

Personalized Antisense Oligonucleotide Therapy for A Single Participant With TARDBP ALS

Active, not recruiting·Nn-Lorem Foundation·Phase 1/2·NCT07095712·1 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for nL-TARD-001. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — nL-TARD-001 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for nL-TARD-001. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — n-Lorem Foundation company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Nn-Lorem Foundation

Related News